{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060893","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.562173+00:00","generated_at":"2026-06-02T00:41:05.992931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunome reports Q1 net loss $129.5M; cash $309.7M extends into 2026; AL102 topline data H2 2025","bullets":["Net loss of $129.5M ($2.51 diluted EPS) includes $112.0M in IPR&D expenses from AL101/AL102 and IM-1021 acquisitions.","Cash, cash equivalents and marketable securities $309.7M as of March 31, 2024; runway expected into 2026.","R&D expense $15.4M; G&A expense $6.0M, including $1.8M stock-based compensation.","Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected second half 2025.","IND submissions for IM-1021 (ROR1 ADC) and IM-3050 (FAP-targeted RLT) expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060893","json":"https://secwatch.observer/filing/0001104659-24-060893.json","markdown":"https://secwatch.observer/filing/0001104659-24-060893.md","text":"https://secwatch.observer/filing/0001104659-24-060893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/0001104659-24-060893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/tm2414252d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:41:05.992931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bc8a672ad250d4449040eccb460e3836a9057f2","claim":"Immunome Inc. reported first quarter ended March 31, 2024 results: net income net loss of $129.5 million, EPS basic and diluted net loss per share attributable to common stockholders of $2.51.","evidence_excerpt":"Immunome, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/0001104659-24-060893-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $129.5 million"},{"label":"EPS","value":"basic and diluted net loss per share attributable to common stockholders of $2.51"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}